Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CPI-613 is effective and safe in either
patients with refractory or relapsed acute myeloid leukemia (AML) or patients with
myelodysplastic syndrome (MDS) who have failed therapy with a hypomethylating agent (such as
decitabine [Vidaza] and azacitidine [AZA]).
Phase:
Phase 2
Details
Lead Sponsor:
Cornerstone Pharmaceuticals, Inc. Rafael Pharmaceuticals Inc.